News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Adds 9 Million IU Version to Its Hepatitis C Treatment Advaferon Injection Series

December 15 ,2004

Tokyo, Japan - December 15, 2004 - Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) launched Advaferon Injection 900, a 9 million IU version of its hepatitis C treatment Advaferon Injection series on December 15.

Advaferon is an interferon (IFN)- developed by combining different amino acids with high incidence based on the amino acid sequences of 13 IFN- subtypes. Since launching in December 2001, the 12 million and 18 million IU versions have been enjoying good reputation as a drug effective for not only genotype 2, low titer chronic hepatitis C but also genotype 1b, high titer chronic hepatitis C, which is refractory to existing therapies.

The new 9 million IU version is suitable for use in elderly patients or when the dosage level needs to be reduced to deal with adverse reactions associated with IFN preparations. The addition of this new version to the existing 12 million and 18 million IU versions is expected to broaden the range of selection in the treatment of chronic hepatitis C.


Product Profile

Brand name:
Advaferon Injection 900

Generic name:
interferon alfacon-1 (genetic recombinant)

Indication:
improvement of viremia associated with chronic hepatitis C

Dosageand administration:
Administer Advaferon Injection after confirming that the patient is HCV-RNA positive. In general, administer 12-18 million IU once a day, daily or 3 times a week, by subcutaneous injection to adults.

Package:
1 vial

NHI price:
9,653yen

Date of launch:
December 15,2004

Manufactured and marketed by:
Yamanouchi Pharmaceutical Co., Ltd.